Pharma giant Eli Lilly said it is negotiating to raise drug prices in Europe, starting in the U.K. with the weight-loss drug ...

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly ( NYSE: LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 ...

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

We recently published 10 Stocks On Jim Cramer’s Radar Including Big Tech Firms. Eli Lilly and Company (NYSE:LLY) is one of ...